Last reviewed · How we verify
Topical pexiganan cream 0.8%
Topical pexiganan cream 0.8% is a Antimicrobial peptide Small molecule drug developed by Dipexium Pharmaceuticals, Inc.. It is currently in Phase 3 development for Diabetic foot ulcers, Infected wounds and skin infections. Also known as: MSI-78.
Pexiganan is an antimicrobial peptide that disrupts bacterial cell membranes, killing a broad spectrum of bacteria including antibiotic-resistant strains.
Pexiganan is an antimicrobial peptide that disrupts bacterial cell membranes, killing a broad spectrum of bacteria including antibiotic-resistant strains. Used for Diabetic foot ulcers, Infected wounds and skin infections.
At a glance
| Generic name | Topical pexiganan cream 0.8% |
|---|---|
| Also known as | MSI-78 |
| Sponsor | Dipexium Pharmaceuticals, Inc. |
| Drug class | Antimicrobial peptide |
| Target | Bacterial cell membrane |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Dermatology |
| Phase | Phase 3 |
Mechanism of action
Pexiganan mimics naturally occurring antimicrobial peptides and works by inserting into and destabilizing bacterial cell membranes, leading to cell lysis and death. Unlike conventional antibiotics that target specific bacterial enzymes or pathways, this mechanism makes it effective against multidrug-resistant organisms. The peptide's broad-spectrum activity and novel mechanism make it particularly useful for topical wound and skin infections.
Approved indications
- Diabetic foot ulcers
- Infected wounds and skin infections
Common side effects
- Application site reactions (erythema, irritation)
- Allergic contact dermatitis
- Pain or burning at application site
Key clinical trials
- Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers (PHASE3)
- Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical pexiganan cream 0.8% CI brief — competitive landscape report
- Topical pexiganan cream 0.8% updates RSS · CI watch RSS
- Dipexium Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Topical pexiganan cream 0.8%
What is Topical pexiganan cream 0.8%?
How does Topical pexiganan cream 0.8% work?
What is Topical pexiganan cream 0.8% used for?
Who makes Topical pexiganan cream 0.8%?
Is Topical pexiganan cream 0.8% also known as anything else?
What drug class is Topical pexiganan cream 0.8% in?
What development phase is Topical pexiganan cream 0.8% in?
What are the side effects of Topical pexiganan cream 0.8%?
What does Topical pexiganan cream 0.8% target?
Related
- Drug class: All Antimicrobial peptide drugs
- Target: All drugs targeting Bacterial cell membrane
- Manufacturer: Dipexium Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Dermatology
- Indication: Drugs for Diabetic foot ulcers
- Indication: Drugs for Infected wounds and skin infections
- Also known as: MSI-78